文献速递血栓与止血贫血与红细胞疾病

重型血友病A婴儿艾美赛珠单抗预防治疗的真实世界FVIII暴露与抑制物发生

Factor VIII exposure, bleeding outcomes, and inhibitor development in 80 previously untreated patients and minimally treated patients with severe hemophilia A on emicizumab prophylaxis: real-world data from the PedNet Registry.
PubMed 文献 · J Thromb Haemost · 2026-07-14

基于PedNet前瞻性注册研究,纳入80例(39例为未经治疗患者)在婴儿期启动艾美赛珠单抗预防治疗的重型血友病A患者,随访中位19.5个月。结果显示FVIII暴露延迟且出血控制良好(年化出血率0.6/年,95%CI 0.4-1.1),5例(2例为未经治疗患者)发生FVIII抑制物,累积发生率35.2%(95%CI 8.6-61.7),未报告严重不良事件或血栓形成。初步分析提示抑制物发生未见减少。

要点

  • 艾美赛珠单抗预防治疗下FVIII首次暴露延迟,中位5.0个月(最小治疗患者)和21.2个月(未经治疗患者)。
  • 年化出血率0.6/年(95%CI 0.4-1.1),出血控制良好,无严重不良事件或血栓形成。
  • 5例发生FVIII抑制物(2例为未经治疗患者),累积发生率35.2%(95%CI 8.6-61.7),初步提示抑制物发生未减少。

核心结论

  • 艾美赛珠单抗预防治疗下FVIII暴露延迟且出血控制良好,无严重不良事件或血栓形成。
  • 初步分析提示FVIII抑制物发生未见减少。

研究设计与样本

  • 前瞻性、观察性、多中心PedNet注册研究,数据截至2025年1月1日。
  • 纳入80例重型血友病A婴儿(39例未经治疗患者),艾美赛珠单抗治疗至少12周,排除HAVEN 7试验参与者。
  • FVIII暴露和抑制物发生采用生存分析。

主要发现

  • 80例婴儿启动艾美赛珠单抗中位年龄8.6个月,随访中位19.5个月。
  • 47/80(59%)婴儿因出血或伴随预防接受FVIII,首次暴露中位时间分别为5.0个月(最小治疗患者)和21.2个月(未经治疗患者)。
  • 年化出血率0.6/年(95%CI 0.4-1.1)。
  • 5例婴儿(2例未经治疗患者)在4至18个暴露日后发生FVIII抑制物,累积发生率35.2%(95%CI 8.6-61.7)。
  • 未报告严重不良事件或血栓形成。

临床怎么用

  • 艾美赛珠单抗预防治疗可用于重型血友病A婴儿早期预防,出血控制良好且安全性可接受。
  • 需监测FVIII抑制物发生,尤其在接受FVIII暴露后。
  • FVIII暴露延迟策略对抑制物发生的影响尚需进一步数据评估。

局限性

  • 初步分析,样本量有限(80例),抑制物事件数少(5例)。
  • 观察性研究设计,可能存在 confounding。
  • 随访时间中位19.5个月,长期抑制物风险需更长时间评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Subcutaneous emicizumab prophylaxis is increasingly used for early prophylaxis in infants with severe hemophilia A (SHA). Although the HAVEN 7 trial (NCT04431726) reported on 55 infants with SHA, real-world information regarding factor (F)VIII exposure, inhibitor development, and bleeding on this age group remains limited. OBJECTIVES: To describe FVIII exposure, model-based annualized bleeding rate, and FVIII inhibitor development in infants with SHA starting emicizumab prophylaxis as previously untreated patients (PUPs) or minimally treated patients (MTPs; 1-5 FVIII-exposure days). METHODS: Data on PUPs and MTPs with SHA on emicizumab for ≥12 weeks were extracted from the prospective, observational multicenter PedNet Registry on January 1, 2025, Participants in HAVEN 7 were excluded. FVIII exposure and inhibitor development were determined by survival analysis. Written informed consent was obtained from all parents/guardians. RESULTS: This study included 80 infants (39 PUPs) starting emicizumab at a median of 8.6 months followed for a median of 19.5 months. During follow-up, 47/80 (59%) infants received FVIII for bleeding or concomitant prophylaxis (n = 10), with delayed first exposure at median 5.0 (MTPs) and 21.2 months (PUPs), respectively. The mean annualized bleeding rate was 0.6/year (95% CI, 0.4-1.1). Five infants (2 PUPs) developed FVIII inhibitors after 4 to 18 EDs, a cumulative incidence of 35.2% (95% CI, 8.6-61.7). No serious adverse events or thrombosis were reported. CONCLUSION: These data show delayed FVIII exposure and good bleeding control without adverse events. Preliminary analysis suggested no decrease in FVIII inhibitor development. PedNet will continue to collect data needed to reliably assess the influence of different FVIII exposure during emicizumab prophylaxis on FVIII inhibitor development in PUPs.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. de Kovel M, Kenet G, Motwani J, et al. Factor VIII exposure, bleeding outcomes, and inhibitor development in 80 previously untreated patients and minimally treated patients with severe hemophilia A on emicizumab prophylaxis: real-world data from the PedNet Registry. J Thromb Haemost. 2026. PMID: 42448013. doi:10.1016/j.jtha.2026.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。